HSD17B13抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-3: HL60 cell, HUVEC cell, HepG2 cell lysates, Primary antibody: P08416(HSD17B13 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08416(HSD17B13 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

HSD17B13 (17β-hydroxysteroid dehydrogenase 13) is a liver-enriched protein belonging to the hydroxysteroid dehydrogenase family, primarily localized to lipid droplets in hepatocytes. It has gained significant attention due to its potential role in lipid metabolism and association with liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Genetic studies revealed that loss-of-function variants in the HSD17B13 gene correlate with reduced risk of progressive liver injury, positioning it as a therapeutic target.

HSD17B13 antibodies are essential tools for detecting and characterizing this protein in research. They enable the study of its expression patterns, subcellular localization, and interaction partners. Commercially available antibodies are typically developed using immunogenic peptides or recombinant protein fragments, validated through techniques like Western blot, immunohistochemistry (IHC), and immunofluorescence (IF). Specificity is often confirmed using HSD17B13 knockout cell lines or tissues.

These antibodies have facilitated discoveries linking HSD17B13 to lipid droplet regulation and inflammatory responses. Recent studies also explore its enzymatic activity in metabolizing bioactive lipids, potentially influencing disease pathways. As drug development targeting HSD17B13 advances (e.g., RNAi therapies), high-quality antibodies remain crucial for preclinical validation and mechanistic studies.